AAN 2026 | Emerging therapeutic strategies for MS at AAN 2026
Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, highlights emerging therapeutic strategies in multiple sclerosis (MS). She discusses strategies targeting smoldering disease, namely BTK inhibitors, and other novel agents being explored, including anti-CD40 therapies. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think that now from all the trials that they are presented I think the most important trials now are all the trials regarding the smoldering disease or the slowly progressing or silent disease and it’s the trials with the BTKs. So that’s the trials for tolebrutinib trials for fenebrutinib and there are some posters about the remibrutinib the design of the study. And that’s I will say that is the big group and I think it’s very important because we want to target the microglia and we want to decrease the progression of the disease because we can control very well the relapses in another part we have some now some studies with the frexalimab that is the anti-CD40 to reduce the relapses and at the same time to reduce the progression...
So I think that now from all the trials that they are presented I think the most important trials now are all the trials regarding the smoldering disease or the slowly progressing or silent disease and it’s the trials with the BTKs. So that’s the trials for tolebrutinib trials for fenebrutinib and there are some posters about the remibrutinib the design of the study. And that’s I will say that is the big group and I think it’s very important because we want to target the microglia and we want to decrease the progression of the disease because we can control very well the relapses in another part we have some now some studies with the frexalimab that is the anti-CD40 to reduce the relapses and at the same time to reduce the progression. And there are some studies now with the vidofludimus that say to try to reduce the also the progression
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving as a Consultant for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for merck. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for roche. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for sanofi. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for novartis. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for viatris. Celia Oreja Guevara has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for biogen. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for bms. Celia Oreja Guevara has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for jannsen.
